Daptomycin: Pharmacology and clinical use

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 4, 2010, Pages 615-625

  Kosmidis, Christos ^a   Levine, Donald P ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Daptomycin; Gram positive infections; Pharmacology; Resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BACTERIAL MUTATION; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COST; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOCARDITIS; ENTEROCOCCAL INFECTION; ERYSIPELAS; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE INFECTION; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NONHUMAN; OSTEOMYELITIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG EVALUATION, PRECLINICAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; VANCOMYCIN RESISTANCE;

EID: 77249116380     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003598893     Document Type: Review

References (80)

1. del Rio A, Cervera C, Moreno A, et al. Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis 2009;48(Suppl 4):S246-53
2. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 2005;25(1):74-85
3. Sievert DM, Boulton ML, Stoltman G, et al. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51(26):565-7
4. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42(6):2398-402
5. Rybak MJ, Lomaestro BM, Rotscahfer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49(3):325-7
6. Available from: http://www.cubicin.com/prescribe.htm
7. Lakey JH, Ptak M. Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry 1988;27(13):4639-45
8. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(8):2538-44
9. Hawkey PM. Pre-clinical experience with daptomycin. J Antimicrob Chemother 2008;62(Suppl 3):iii7-14
10. Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007;51(12):4255-60
11. Hobbs JK, Miller K, O'Neill AJ, Chopra I. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 2008;62(5):1003-8
12. Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44(11):2948-53
13. Suh B. Resolution of persistent Pediococcus bacteremia with daptomycin treatment: case report and review of the literature. Diagn Microbiol Infect Dis 2010;66(1):111-5
14. King A, Phillips I. The in vitro activity of daptomycin against 514 gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001;48(2):219-23
15. Golan Y, Poutsiaka DD, Tozzi S, et al. Daptomycin for line-related Leuconostoc bacteraemia. J Antimicrob Chemother 2001;47(3):364-5
16. Citron DM, Appleman MD. In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of Bacillus species. J Clin Microbiol 2006;44(10):3814-8
17. Spanjaard L, Vandenbroucke-Grauls CM. Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid. Antimicrob Agents Chemother 2008;52(5):1850-1
18. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 2003;47(1):337-41
19. Silva M, Jacobus NV, Gorbach SL. In vitro activity of LY146032 against gram-positive bacteria. Diagn Microbiol Infect Dis 1988;9(2):79-85
20. Sader HS, Jones RN. Evaluation of daptomycin activity tested against 35058 bacterial strains from hospitalized patients: summary of a 7 year surveillance program for North America (2002-2008). Abstract #199. 47th Annual Meeting of the Infectious Diseases Society of America, 30 October 2009; Philadelphia, PA
21. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50(10):3245-9
22. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47(4):1318-23
23. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of gram-positive infections. Expert Opin Investig Drugs 2004;13(9):1159-69
24. Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004;150(2):137-47
25. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191(12):2149-52
26. Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 2009;64(1):151-8
27. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47(5):1598-603
28. Alder J, Li T, Yu D, et al. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrob Agents Chemother 2003;47(11):3561-6
29. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004;48(1):63-8
30. Louie A, Kaw P, Liu W, et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001;45(3):845-51
31. Rybak MMP, Cha R, Dvorchik B. Daptomycin Pharmacodynamics (PD) versus MRSA at Various Doses as Assessed by a Monte Carlo Prediction Model. Abstract A-2195. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL; 16-19 Dec 2001
32. Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 1991;35(9):1710-6
33. Credito K, Lin G, Appelbaum PC. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 2007;51(4):1504-7
34. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004;48(8):2871-5
35. Miro JM, Garcia-de-la-Maria C, Armero Y, et al. The addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:4172-7
36. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004;53(3):530-2
37. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005;49(12):5166-8
38. Steenbergen JN, Mohr JF, Thorne GM. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009;64(6):1130-8
39. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355(7):653-65
40. Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 2006;57(3):578-9
41. Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006;42(12):e108-10
42. Odero RO, Cleveland KO, Gelfand MS. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother 2009;63(6):1299-300
43. Webster PS, Oleson FB Jr, Paterson DL, et al. Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. Blood Coagul Fibrinolysis 2008;19(1):32-8
44. Levine DP. Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother 2008;62(Suppl 3):iii35-9
45. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12):1673-81
46. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55(2):240-5
47. Owens RC Jr, Lamp KC, Friedrich LV, Russo R. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med 2007;120(10 Suppl 1):S6-12
48. Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract 2009;63(3):368-75
49. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008;62(9):1455-64
50. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007;120(10 Suppl 1):S13-20
51. Forrest GN, Donovan BJ, Lamp KC, Friedrich LV. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis. Ann Pharmacother 2008;42(2):213-7
52. Antony SJ, Angelos E, Stratton CW. Clinical experience with daptomycin in patients with orthopedic-related infections. Infect Dis Clin Pract 2006;14(3):144-9
53. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 2005;21(12):1923-6
54. Bhavnani SM, Prakhya A, Hammel JP, Ambrose PG. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Clin Infect Dis 2009;49(5):691-8
55. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008;62(6):1413-21
56. Martone WJ, Lindfield KC, Katz DE. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract 2008;62(8):1183-7
57. VanAnglen L. Comparison of outpatient antibiotic therapy use of daptomycin, linezolid, quinupristin/dalfopristin, tigecycline, and vancomycin in physician-operated office infusion centers. Abstract K-1380. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America. 46th Annual Meeting; Washington DC, 2008. p. 483
58. Gallagher JC, Perez ME, Marino EA, et al. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009;29(7):792-9
59. Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 2009;64(1):175-80
60. Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009;33(6):543-8
61. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38(7):994-1000
62. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006;50(6):2137-45
63. Kaatz GW, Lundstrom TS, Seo SM. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 2006;28(4):280-7
64. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008;52(1):269-78
65. Mishra NN, Yang SJ, Sawa A, et al. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53(6):2312-8
66. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45(6):1799-802
67. Patel JB, Jevitt LA, Hageman J, et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006;42(11):1652-3
68. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006;50(3):1079-82
69. Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006;50(4):1581-5
70. Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci 2007;104(22):9451-6
71. Picazo JJ, Betriu C, Culebras E, et al. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Diagn Microbiol Infect Dis 2009;64(4):448-51
72. Mathai D, Biedenbach DJ, Jones RN, et al. Activity of daptomycin against Gram-positive bacterial isolates from Indian medical centres (2006-2007). Int J Antimicrob Agents 2009;34(5):497-9
73. Malli E, Spiliopoulou I, Kolonitsiou F, et al. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece. Int J Antimicrob Agents 2008;32(6):525-8
74. Hidron AI, Schuetz AN, Nolte FS, et al. Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother 2008;61(6):1394-6
75. Montero CI, Stock F, Murray PR. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob Agents Chemother 2008;52(3):1167-70
76. Schwartz BS, Ngo PD, Guglielmo BJ. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Ann Pharmacother 2008;42(2):289-90
77. Hirschwerk D, Ginocchio CC, Bythrow M, Condon S. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2006;27(3):315-7
78. Sakoulas G, Rose W, Rybak MJ, et al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol 2008;46(1):220-4
79. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40(7):1058-60
80. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007;60(2):334-40